Table 5.

Relative dose intensity in demographic and clinical subgroups.

	Median	IQR	Unadjusted P-value1	Adjusted P-value2
All women (N = 325)	0.88	0.77-0.94	—	—
Age (years)			0.88	—
<40	0.87	0.77-0.95
40-50	0.87	0.76-0.95
50-60	0.89	0.81-0.94
60-70	0.87	0.76-0.93
≥70	0.92	0.76-0.96
Marital status			0.98	—
Married	0.89	0.78-0.94
Unmarried	0.88	0.77-0.95
Education			0.94	—
None or primary only	0.87	0.77-0.95
Secondary or beyond	0.87	0.77-0.95
Wealth index (percentile)			0.89	—
<20th	0.89	0.78-0.95
20-40th	0.86	0.75-0.94
40-60th	0.88	0.77-0.93
60-80th	0.91	0.76-0.96
≥80th	0.86	0.79-0.95
Treating hospital			0.24	—
CMJAH	0.88	0.76-0.95
GH	0.88	0.79-0.94
Year of diagnosis			0.12	—
2015-2016	0.9	0.80-0.95
2017-2019	0.87	0.77-0.94
Stage			0.14	—
I-II	0.87	0.74-0.94
III	0.87	0.78-0.95
Grade			0.29	—
1-2	0.88	0.76-0.94
3	0.89	0.80-0.95
ER/PR status			0.02	0.04
Positive	0.9	0.79-0.95
Negative	0.84	0.73-0.93
HER2 status			0.02	0.047
Positive	0.9	0.80-0.97
Equivocal	0.89	0.80-0.95
Negative	0.87	0.76-0.94
Pre-chemotherapy ECOG performance status			0.07	0.08
0	0.87	0.76-0.94
1	0.90	0.81-0.95
2	0.93	0.80-0.97
HIV status			0.7	0.70
Positive	0.89	0.77-0.95
Negative	0.87	0.77-0.94

¹ Univariable linear regression.

² Multivariable linear regression with ER/PR status, HER2 status, performance status, and HIV status included as covariates.

Abbreviations: CMJAH, Charlotte Maxeke Johannesburg Academic Hospital; ER/PR, estrogen receptor/progesterone receptor; GH, Grey’s Hospital; HER2, human epidermal growth factor receptor 2; IQR, interquartile range.